Scholarlink

Purpose <p>Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease causing significant morbidity. Biologics such as dupilumab (anti-IL-4Ra) and mepolizumab (anti-IL-5) are effective treatments; however, comparative real-world data remain limited. This study evaluates their effectiveness over the first six months in patients with uncontrolled primary diffuse Type 2 chronic rhinosinusitis.</p> Methods <p>A retrospective analysis was conducted on 85 CRSwNP patients treated at Padova University Hospital (58 dupilumab, 27 mepolizumab). Patient-reported (SNOT-22, VAS scores) and clinician-reported (NPS, SSIT, PNIF) outcomes were assessed at baseline (T0), one month (T1), three months (T3), and six months (T6).</p> Results <p>Dupilumab showed a rapid and significant improvement in all assessed PROMs and CROMs (<i>p</i> &lt; 0.001), with a marked reduction in nasal polyp size and superior early olfactory recovery. By six months, 17% of dupilumab-treated patients achieved normosmia versus 7% in the mepolizumab group. Mepolizumab improved most outcomes except VAS-smell and significantly reduced blood eosinophil counts (<i>p</i> &lt; 0.001), whereas dupilumab had no significant effect. According to EUFOREA 2023 criteria, 70% of dupilumab-treated patients had a moderate to excellent response versus 37% in the mepolizumab group.</p> Conclusion <p>Both biologics are effective for CRSwNP, but their efficacy profiles differ. Dupilumab provides faster olfactory and nasal polyp improvements. Personalized biologic selection is essential, and further studies are needed to define long-term outcomes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Early real-life outcomes of dupilumab and mepolizumab in patients with uncontrolled primary diffuse type 2 chronic rhinosinusitis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月18日

查看全文
  • Tommaso Saccardo,
  • Giuseppe Roccuzzo,
  • Nicola Tessari,
  • Sonny Zampollo,
  • Alessandro Fontana,
  • Bruno Scarpa,
  • Piero Nicolai,
  • Giancarlo Ottaviano

摘要

Purpose

Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease causing significant morbidity. Biologics such as dupilumab (anti-IL-4Ra) and mepolizumab (anti-IL-5) are effective treatments; however, comparative real-world data remain limited. This study evaluates their effectiveness over the first six months in patients with uncontrolled primary diffuse Type 2 chronic rhinosinusitis.

Methods

A retrospective analysis was conducted on 85 CRSwNP patients treated at Padova University Hospital (58 dupilumab, 27 mepolizumab). Patient-reported (SNOT-22, VAS scores) and clinician-reported (NPS, SSIT, PNIF) outcomes were assessed at baseline (T0), one month (T1), three months (T3), and six months (T6).

Results

Dupilumab showed a rapid and significant improvement in all assessed PROMs and CROMs (p < 0.001), with a marked reduction in nasal polyp size and superior early olfactory recovery. By six months, 17% of dupilumab-treated patients achieved normosmia versus 7% in the mepolizumab group. Mepolizumab improved most outcomes except VAS-smell and significantly reduced blood eosinophil counts (p < 0.001), whereas dupilumab had no significant effect. According to EUFOREA 2023 criteria, 70% of dupilumab-treated patients had a moderate to excellent response versus 37% in the mepolizumab group.

Conclusion

Both biologics are effective for CRSwNP, but their efficacy profiles differ. Dupilumab provides faster olfactory and nasal polyp improvements. Personalized biologic selection is essential, and further studies are needed to define long-term outcomes.